Latest Antianginals Stories
Corlanor is the First New Chronic Heart Failure Medicine Approved by the FDA in Nearly a Decade THOUSAND OAKS, Calif., April 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that
DALLAS, January 6, 2015 /PRNewswire/ -- ReportsnReports.com adds "Global Isosorbide Market 2015-2019", a 58 pages Isosorbide business intelligence report, talking about
Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.
Considerable Opportunity Exists for Therapies Offering Reductions in Mortality and Hospitalization Rates, According to Findings from Decision Resources Group BURLINGTON, Mass., April 14, 2014
A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control.
The explosive PETN has been around for a century and is used by everyone from miners to the military, but it took new research by Sandia National Laboratories to begin to discover key mechanisms behind what causes it to fail at small scales.
Despite the fact that nifedipine increases the risk of heart attacks and death, doctors still prescribe this immediate-release blood pressure drug to elderly patients.
- Growing in low tufty patches.